XRAY
DENTSPLY SIRONA Inc.
$8.87
+5.34% 2026-10-20
Health CareS&P 400
XRAYSPY
1W
+4.2%
1M
-7.0%
3M
-35.0%
6M
-27.9%
YTD
-22.4%
1Y
-30.4%
Live chart
Loading live chart…
Grades vs sector
Momentum9th pct in sectorD-
Momentum
9th pct in sector
12-1 return: -28.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth5th pct in sectorF
Growth
5th pct in sector
Revenue growth (YoY): -4.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value95th pct in sectorA+
Value
95th pct in sector
Forward E/P: 17.4% · EBITDA/EV: 13.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability7th pct in sectorF
Profitability
7th pct in sector
Profit margin: -15.0% · Return on equity: -33.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsDentsply Sirona to Host Third Quarter 2026 Conference Call on November 5
GlobeNewswire · 8h ago
Global Clear Aligners Market Size, Share, Trends, and Forecast to 2031 | Image-Conscious Adults Set to Nearly Double the Clear Aligner Market to $11bn Market Value
GlobeNewswire · 19h ago
U.S. Digital Dentistry Market to Top $1.6B by 2032 as Clear Aligners and DSOs Drive Intraoral Scanner and 3D Printer Adoption
GlobeNewswire · Oct 14
Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal
Zacks · Oct 12
Dentsply Sirona (XRAY): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · Oct 09
Key stats
Market cap$1.8B
P/E (trailing)–
P/E (forward)5.9
52-week range8.32 – 14.76
Revenue growth (YoY, latest qtr)-4.1%
Dividend yield0.00%
Analyst consensusHold (15)
Mean price target$12.67 (+43%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 96%
▲Forward P/E vs sector5.9x vs median 17.6x
•Piotroski F-score6/9
▼Altman Z0.5 (distress)
▼Net debt / EBITDA51.0x
▲Analyst target+43% (15 analysts)
Discounted cash flow
Bear
$-3
-139%
growth -8% · disc. 9.6% · term. 2.0%
Base
$0
-96%
growth -3% · disc. 8.6% · term. 2.5%
Bull
$6
-35%
growth -0% · disc. 7.6% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 6% a year for 10 years.
Implied
+6%/yr
FCF, last 3 yrs
-14%/yr
FCF, last 5 yrs
-16%/yr
Revenue, last 3 yrs
-2%/yr
Revenue, last 5 yrs
+2%/yr
Same inputs as the DCF above: trailing free cash flow 0.2B, 8.6% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.88 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
sector median 29.9×
–Forward P/E
cheaper
sector median 17.6× · 4th pct
5.9×cheaper
EV / EBITDA
pricier
sector median 15.8× · 97th pct
96.4×pricier
Price / sales
cheaper
sector median 3.1× · 8th pct
0.5×cheaper
Price / book
cheaper
sector median 3.5× · 8th pct
1.3×cheaper
FCF yield
cheaper
sector median 4.1% · 89th pct
9.6%cheaper
Forward EPS $1.50 vs trailing $-2.73. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$28.4M
as of 2020-09-30
vs a year ago
–
YoY
× TTM revenue
0.01×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
49.5%
Operating margin
-8.5%
FCF margin
4.7%
Net margin
-15.0%
Return on equity
-40.4%
Return on invested capital
-7.3%
Net debt / EBITDA
51.0×
Current ratio
1.6×
Interest cover
-3.4×
Cash conversion (OCF/NI)
–
Piotroski F-score 6/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 0.5 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$13
+43%
Analysts
15
Hold
Range
$9–$17
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.7B | $-598.0M | $235.0M |
| 2024 | $3.8B | $-910.0M | $461.0M |
| 2023 | $4.0B | $-132.0M | $377.0M |
| 2022 | $3.9B | $-950.0M | $368.0M |
| 2021 | $4.2B | $411.0M | $515.0M |
| 2020 | $3.3B | $-73.0M | $562.0M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -2.1%.
Earnings
Next report: 2026-11-05 · during market · EPS est 0.31
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 0.35 | 0.52 | +50.1% |
| 2026-05-05 | 0.27 | 0.27 | -1.6% |
| 2026-02-26 | 0.29 | 0.27 | -6.0% |
| 2025-11-06 | 0.45 | 0.37 | -17.7% |
| 2025-08-07 | 0.50 | 0.52 | +3.1% |
| 2025-05-08 | 0.30 | 0.43 | +43.2% |
| 2025-02-27 | 0.43 | 0.26 | -40.1% |
| 2024-11-07 | 0.48 | 0.50 | +5.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $898.0M | -4.1% |
| 2026-03-31 | $880.0M | – |
| 2025-12-31 | $961.0M | – |
| 2025-09-30 | $904.0M | – |
| 2025-06-30 | $936.0M | – |
Analyst actions
Leerink Partners
PT $10
2026-10-14 · main
Market Perform → Market PerformPT $10
Piper Sandler
PT $12
2026-10-09 · main
Neutral → NeutralPT $12
BMO Capital
PT $10
2026-09-17 · main
Market Perform → Market PerformPT $10
Barclays
PT $11
2026-08-24 · main
Underweight → UnderweightPT $11
Piper Sandler
PT $14
2026-07-29 · main
Neutral → NeutralPT $14
BMO Capital
PT $12
2026-07-09 · init
→ Market PerformPT $12
Recent dividends
2025-12-26: $0.160 · 2025-09-26: $0.160 · 2025-06-27: $0.160 · 2025-03-28: $0.160 · 2024-12-27: $0.160 · 2024-09-27: $0.160 · 2024-06-28: $0.160 · 2024-03-27: $0.160
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:14:05 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.